U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.
HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...
The US Food and Drug Administration (FDA) plans to add a “black box” warning to COVID-19 vaccines, CNN reported, citing two ...
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...
On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...
FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...
The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...
The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...
The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...
FDA officials have opened a safety review of two injectable RSV drugs used to protect babies and toddlers from the ...
Belgian scientists from VIB and Ghent University (UGent), together with Danish collaborators, have uncovered compelling evidence that early-infancy infection with respiratory syncytial virus (RSV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback